Compounds and compositions and methods of use

Details Compounds and compositions and methods of use Compounds and compositions and methods of use

2008-11-26

2011-12-27

Shameem, Golam M M (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S262200, C548S263800, C514S383000

Reexamination Certificate

active

08084483

ABSTRACT:
Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

REFERENCES:
patent: 4198513 (1980-04-01), Baldwin et al.
patent: 5939462 (1999-08-01), Connell et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6245817 (2001-06-01), Connell et al.
patent: 6414147 (2002-07-01), Currie et al.
patent: 7435752 (2008-10-01), Girardet et al.
patent: 7642277 (2010-01-01), Simoneau et al.
patent: 7683087 (2010-03-01), Girardet
patent: 7947721 (2011-05-01), Girardet et al.
patent: 2002/0026186 (2002-02-01), Woloszko et al.
patent: 2003/0027433 (2003-02-01), Faur et al.
patent: 2005/0054639 (2005-03-01), Simoneau et al.
patent: 2006/0135556 (2006-06-01), Girardet et al.
patent: 2006/0270725 (2006-11-01), Girardet et al.
patent: 2008/0176850 (2008-07-01), Girardet et al.
patent: 2010/0069645 (2010-03-01), Girardet et al.
patent: 2010/0081827 (2010-04-01), Girardet
patent: 2010/0137590 (2010-06-01), Girardet et al.
patent: 2010/0267724 (2010-10-01), Girardet et al.
patent: 1050531 (1979-03-01), None
patent: 7215940 (1995-08-01), None
patent: WO-00-27850 (2000-05-01), None
patent: WO-02-070470 (2002-09-01), None
patent: WO-03-016306 (2003-02-01), None
patent: WO-03-097047 (2003-11-01), None
patent: WO-2004-030611 (2004-04-01), None
patent: WO-2004-050643 (2004-06-01), None
patent: WO-2004-069812 (2004-08-01), None
patent: WO-2005-028479 (2005-03-01), None
patent: WO-2005-087750 (2005-09-01), None
patent: WO-2006-026356 (2006-03-01), None
patent: WO 2006/026356 (2006-03-01), None
patent: WO-2007-050087 (2007-05-01), None
patent: WO 2007/139951 (2007-12-01), None
patent: WO 2007/140002 (2007-12-01), None
patent: WO-2010-048592 (2010-04-01), None
Supplementary EP Search Report and Opinion mailed Nov. 11, 2010.
Request for Republication Under 35 [sic, 37] CFR 1.221(a), filed on Jun. 2, 2010, for U.S. Appl. No. 11/661,079.
Office Action dated Oct. 12, 2010 for U.S. Appl. No. 12/633,638.
Certificate of Correction dated Jul. 13, 2010 for US Patent No. 7,683,087 B2.
Office Action dated Aug. 11, 2009 for U.S. Appl. No. 12/193,599.
Certificate of Correction dated Dec. 22, 2009 for US Patent No. 7,435,752 B2.
Office Action dated Nov. 30, 2007 for U.S. Appl. No. 11/291,653.
Office Action dated Jun. 28, 2010 for U.S. Appl. No. 11/661,079.
Office Action dated Jan. 3, 2011 for U.S. Appl. No. 11/661,079.
Notice of Allowance dated Feb. 3, 2011 for U.S. Appl. No. 11/661,079.
Anzai et al., :The Multivalent PDZ Domain-containing Protein PDZK1 Regulates Transport Activity of Renal Urate-Anion Exchanger URAT1 via Its C Terminus, J. Biol. Chem. 279:45942-45950 (2004).
Bundgaard, “Design and Application of Prodrugs,” in Textbook of Drug Design and Development, Krosgaard-Larsen and Bundgaard, ed. 1991, Chapter 5, pp. 113-191 (1991).
Enomoto et al., “Molecular identification of a renal urate-anion exchanger that regulates blood urate levels,” Nature 417:447-452 (2002).
Fleisher et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs,” Advanced Drug Delivery Reviews 19:115 (1996).
Furniss et al., eds.; Vogel's Encyclopedia of Practical Organic Chemistry, 5thSupp., Longman Scientific and Technical Ltd., Essex, 1991, pp. 809-816.
Heller, A., “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res. 23:128-134 (1990).
Saulnier et al., “An Efficient Method for the Synthesis of Guandino Prodrugs,” Bioorg. Med. Chem. Ltrs. 4(16):1985-1990 (1994).
Zhang, Z. et al., “A Novel Nonnucleoside Analogue That Inhibits Human Immunodeficiency Virus Type I Isolates Resistant to Current Nonnucleoside Reverse Transcriptase Inhibitors,” Antimicrobial Agents and Chemotherapy 51(2):429-437 (2007).
PCT/US08/84988 Search Report dated Jun. 23, 2009.
Tantawy, et al. Development of some triazole and oxadiazole derivatives as potential CNS depressant agents, Alexandria Journal of Pharmaceutical Sciences (1988), 2(1), 50-3. (CAS Accession No. 1989:407302).
Ainsworth, C. “1,2,4-Triazole” Org. Syn., Coll.; vol. 5: 1070. (4 pages) (1973).
Badger, et al. “Azaindoles. III. The synthesis of pyrazolo[3,4-b]pyridines and pyrazolo-[3,4-d]pyrimidines” Aust. J. Chem.; 18(8): 1267-71 (1965).
Berge, et al. “Pharmaceutical salts” J. Pharm. Sci.; 66(1): 1-19 (1977).
Bontems, et al. “Guanosine analogues: Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents” J. Med. Chem.; 33(8): 2174-8 (1990).
Connor, et al. “Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection” J. Virol.; 70(8): 5306-11 (1996).
Fleishmann, R., et al. “Lesinurad (RDEA594), A Novel Uricosuric Agent, in Combination with Febuxostat Shows Significant Additive Urate Lowering Effects . . . ” (May 25-28, 2011).
Girardet, J.L., et al. “The Discovery of RDEA806, a Potent new HIV NNRT in Phase 1 Clinical Trials” (Sep. 17-20, 2007).
Hamatake, et al. “RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance” (Sep. 17-20, 2007).
Hamatake, R., et al. “An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins” (Feb. 3-6, 2008).
Harrington, et al. “Direct detection of infectious HIV-1 in blood using a centrifugation-indicator cell assay” J. Virol. Methods. 88(1): 111-5 (2000).
Ibata, et al. “Formation and reaction of oxazoles: Synthesis of N-substituted 2-(aminomethyl)oxazoles” Bull. Chem. Soc. Jpn.; 62: 618-20 (1989).
Ibata, et al. “The acid catalyzed decomposition of diazo compounds. I. Synthesis of oxazoles in the BF3 catalyzed reaction of diazo carbonyl compounds with nitriles” Bull. Chem. Soc. Jpn.; 52: 3597 (1979).
Kerr, B., et al. “Pharmacokinetics and Serum Urate Lowering Effect of RDEA594, A Novel URAT1 Inhibitor, In Gout Patients and Subjects with Varying . . . ” (Mar. 2-5, 2011).
Larsen, et al. “Prodrug forms for the sulfonamide group. I: Evaluation of N . . . ” (1987).
Lasko, B., et al. “RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in . . . ” (Oct. 16-21, 2009).
Lewis, et al. “Pyrazolopyrimidine nucleosides. 13. Synthesis of the novel C . . . ” J Am Chem Soc 104:1073-1077 (1982).
Liu, et al. “An improved synthesis of 9-Deazaguanine” Synthetic Comm 32(24): 3797-3802 (2002).
Lopes, et al. “Acyloxymethyl as a drug protecting group. Part 6: N . . . ” (2000).
Ludovici, et al. “Evolution of anti-HIV Drug Candidates” Bioorg. & Med. Chem. Ltrs 2235-2239 (2001).
Modi et al., “Synthesis of substituted 1,2 arylhydrazones of 4-ary1-4H-1,2,4-triazoly1-3-thioacetic acid hydrazides,” J. Indian Chem. Soc. 54:1087-1089 (1977).
Modi et al., “Synthesis of S-(4-aryl-4H-1,2,4-triazol-3y1)2-mercaptomethyl benuimidazoles,” J. Indian Chem. Soc. 54:741-742 (1977).
Olesen, P. “The use of bioisosteric groups in lead optimization” Current Opinion in Drug Discovery & Development.; 4(4): 471(2001).
Patani, et al. “Bioisosterism: A rational approach in drug design” Chem. Rev.; 96(8): 3147 (1996).
Perez-Ruiz, F., et al. “Efficacy and Safety of RDEA594, a Novel Uricosuric Agent, as Combination Therapy with Allopurinol in Gout Patients: Randomized, . . . ” (Jun. 16-19, 2010).
Platt, et al. “Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1” J. Virol.; 72(4): 2855 (1998).
Popik, et al. “Human immunodeficiency virus type 1 uses lipid raft . . . 

Affiliated with

Also associated with

Rating

Compounds and compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4265267